Clin2
NCT06841731Possibly a fitRecruiting

Testing a new antibiotic for hospital-acquired pneumonia

Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)

Treatments studied

Part of Infections, Lungs & breathing clinical trials.

This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have been diagnosed with bacterial pneumonia that started in the hospital or while on a breathing machine
  • You need to be in the hospital to receive antibiotics through an IV
  • Your chest X-ray shows new or worsening signs of pneumonia
  • You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 2 weeks after treatment ends
  • You have not taken strong antibiotics for this pneumonia for more than 24 hours in the last 3 days

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07326540Recruiting· Phase 3
Testing a new antibiotic for drug-resistant pneumonia in the hospital

This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.

Tbilisi
NCT07634198Not yet recruiting· Phase 3
New antibiotic for hospital-acquired pneumonia in adults

This trial tests a new antibiotic called YK-1169 compared to a standard antibiotic (ceftazidime-avibactam) in adults with serious lung infections acquired in hospitals or from ventilators. The goal is to see if YK-1169 works as well or better at treating these infections.

NCT07089186Recruiting· Phase 3
Study of meropenem and pralurbactam for certain antibiotic-resistant infections

This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.

Shanghai
NCT07431307Not yet recruiting· Phase 2
Combination antibiotics for resistant Acinetobacter infections

This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.

NCT07759934Recruiting· Phase 2
Comparing ASK0912 to polymyxin B for hospital-acquired pneumonia

This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.

Nanjing, Jiangsu
NCT07327619Recruiting· Phase 3
Testing a New Antibiotic Combo for Hospital-Acquired Pneumonia

This trial tests a combination of two antibiotics (meropenem and pralurbactam) to see if they work better than other treatments for people with pneumonia that started in the hospital or from a breathing machine. If you qualify, this study might offer you a new treatment option.

Huaihua, Hunan

Hear when a new Hospital-acquired Bacterial Pneumonia (HABP) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.